



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 802 782 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
05.02.2003 Bulletin 2003/06

(51) Int Cl.⁷: **A61K 7/40, A61K 7/42,
A61K 7/44, A61K 7/48**

(21) Application number: **95940004.5**

(86) International application number:
PCT/US95/14920

(22) Date of filing: **16.11.1995**

(87) International publication number:
WO 96/015771 (30.05.1996 Gazette 1996/25)

(54) **PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION**

**PROPHYLAKTISCHE UND THERAPEUTISCHE BEHANDLUNG VON HAUPT SENSIBILISIERUNG
UND -REIZUNG**

**TRAITEMENT PROPHYLACTIQUE ET THERAPEUTIQUE DE LA SENSIBILISATION ET DE
L'IRRITATION CUTANEE**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **22.11.1994 US 343156**

(43) Date of publication of application:
29.10.1997 Bulletin 1997/44

(73) Proprietor: **BRISTOL-MYERS SQUIBB COMPANY**
Skillman, NJ 08558 (US)

(72) Inventors:
• **WILLE, John J.**
Trenton, NJ 08620 (US)

• **KYDONIEUS, Agis**
Kendall Park, NJ 08824 (US)

(74) Representative: **Mays, Julie et al**
Barker Brettell,
10-12 Priests Bridge
London SW15 5JE (GB)

(56) References cited:
EP-A- 0 247 507 **US-A- 4 897 260**

• **CHEMICAL ABSTRACTS, Volume 121, REDRUP**
et al., "Effect of Loop Diuretics on Rat Peritoneal
and Human Lung Mast Cells", Abstract Number
124876; & AGENTS ACTIONS, issued 1994,
pages C47-C48.

EP 0 802 782 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**RELATED APPLICATIONS**

5 **[0001]** This is a Continuation-In-Part Application of U.S. Serial No. 08/343,156 filed on November 22, 1994.

FIELD OF THE INVENTION

10 **[0002]** The present invention relates to transdermal delivery systems and uses for the manufacture of medicaments for preventing or treating adverse reactions of the skin to skin-sensitizing or skin-irritating agents.

BACKGROUND OF THE INVENTION

15 **[0003]** The skin is susceptible to penetration by agents that sensitize the skin or irritate the skin. As used herein the term "skin-sensitizing agent" is a substance that generally causes the formation of memory cells which recognize future contact with the sensitizing agent. Such future contact can result in an adverse reaction, both locally and at remote sites on the body. In general, a "skin-irritating agent" is a substance (e.g. soap) that causes an immediate and generally localized adverse response. The response is typically in the form of redness and/or inflammation and does not extend beyond the immediate area of contact nor does it cause the formation of memory cells. As used herein, the term
20 "adverse skin reaction preventing or treating agent" shall mean collectively agents used in the present invention against skin-sensitizing agents and/or skin-irritating agents.

[0004] Allergic reactions of the skin to skin-sensitizing agents, known as allergic contact dermatitis (ACD), are immune responses that occur in the skin. The response is the result of the penetration of the skin by a foreign substance (e.g. hapten or antigen) that provokes a skin sensitization reaction. ACD is a two phase process involving an initial
25 induction phase followed by an elicitation phase.

[0005] The induction phase occurs immediately after first time exposure of the skin to the hapten or antigen and is characterized by the formation of immune memory cells that can subsequently recognize the specific hapten or antigen which previously entered the skin for the first time.

[0006] The elicitation phase occurs when the skin is subsequently re-exposed to the original hapten or antigen. In the elicitation phase, the skin provides an overt reaction to the presence of the hapten or antigen in the form of a skin
30 inflammatory response.

[0007] ACD generally results in a life-time persistent memory for the specific hapten or antigen. Thus, when the skin is exposed to the hapten or antigen at a subsequent time, there is typically an immediate and often severe skin inflammatory response.

35 **[0008]** Agents that cause allergic contact dermatitis are varied and numerous and include, for example, metals (e.g. nickel, chromium, cobalt and the like) fragrances, chemicals, cosmetics, textiles, pesticides, plastics, pollen and the like (see, for example, R.J.G. Rycroft et al. "Textbook of Contact Dermatitis"). Therapeutic agents such as drugs may also cause allergic contact dermatitis particularly when administered transdermally.

[0009] Transdermal delivery of drugs provides many advantages over alternate routes of administration. Transdermal delivery systems (TDS) for delivery of drugs or other beneficial agents are well-known (see, for example, U.S. Patent
40 Nos. 3,598,122, 3,598,123, 4,286,592, 4,314,557, 4,379,454, 4,599,222 and 4,573,995). A TDS is generally composed of the following components: (a) "basic components", including backing, matrix reservoir, and an optional separate adhesive layer; (b) the drug or other therapeutic agent; (c) "additives", including solubilizers, plasticizers and permeation enhancers; and (d) "impurities" such as residual amounts of monomers, initiators, cross-linkers, etc., from the polym-
45 erization process during fabrication of the basic components.

[0010] The conditions under which TDS are administered are highly conducive to the induction of skin allergic reactions, and the following skin reactions may be expected to occur:

1. Irritant reactions to the drug, an additive, an impurity, or a combination thereof;
- 50 2. Allergic reactions, especially to the low molecular weight components (drug, additive, impurity, adhesive);
3. Local sweat retention syndrome resulting from prolonged skin occlusion which causes blocking of sweat ducts.

55 **[0011]** Allergic contact dermatitis presents a significant problem in the transdermal administration of therapeutic agents. It is well known that many drugs, including some currently marketed in the United States (e.g. clonidine) sensitize the skin when used in a transdermal delivery system. Skin sensitization may be produced not only by the transdermally delivered drug, but also by a non-sensitizing drug combined with skin sensitizing permeation enhancers, or a combination of a sensitizing drug and a sensitizing permeation enhancer. Penetration of these sensitizing agents into the skin and the resulting adverse reaction of the skin may persist well beyond the time that the transdermal patch is

removed from the skin. The reaction of the skin may be a source of discomfort and a clinical complication in a patient suffering from such a reaction.

[0012] Unlike the response induced by skin-sensitizing agents, the non-allergic response to skin-irritating agents is immediate and localized and does not invoke activation of the immune system through the production of immune memory cells.

[0013] The most common response associated with skin-irritating agents is the onset of inflammation. The main steps of the inflammatory response include, the neurologic phase, the vascular phase and the cellular phase. In the neurologic phase transient vasoconstriction occurs typically within about 30 seconds of contact with the skin-irritating agent. Within about one to six minutes of contact, vasodilation occurs followed by the margination of neutrophils in the vessels and diapedesis, the outward passage of corpuscular elements through intact vessel walls.

[0014] The non-immune response to a skin-irritating agent is the result of a substance that causes direct toxic damage to the skin without preceding allergic sensitization. The response to contact is dependent upon the nature of the skin, the skin-irritating agent, its concentration, the situs of contact on the body and environmental factors such as humidity and temperature. Examples of potential skin-irritating agents include water, skin cleansers, industrial cleaning agents, alkalis, acids, oils, organic solvents, oxidizing agents, reducing agents, plant matter, animal matter, combinations thereof and the like.

[0015] Efforts have been made to address the problem of allergic contact dermatitis by prophylactically treating the skin to prevent the onset of the induction phase of ACD and/or to therapeutically prevent or reduce the adverse effects of the elicitation phase of ACD. For example, U.S. Patent No. 5,202,130 discloses that lanthanide ions and organic calcium channel blockers individually can be used for the treatment of contact allergic dermatitis.

[0016] Wolfgang Diezel et al., *J. Invest. Derm.*, Vol. 93, No. 3, pp. 322-326 (September 1989) discloses the sensitization of mice with 1-chloro-2, 4-dinitrobenzene and subsequent treatment with lanthanum citrate and diltiazem hydrochloride to prevent the onset of the induction phase of the sensitizing agent. Philip W. Ledger, et al., U.S. Patent No. 5,120,545 disclose the prevention of skin sensitization by the administration of an antigen processing-inhibiting agent such as ammonium chloride. A method of preventing contact sensitization using steroids (e.g. corticosteroid and glucocorticoid carboxylic acid esters) is disclosed, for example, in Alfred Amkraut, U.S. Patent No. 5,118, 509 and Peter M. Ross, et al., U.S. Patent No. 4,897,260.

[0017] A method of reducing the adverse effects of administering a sensitizing or irritating drug by using methyl nicotinate is disclosed in Michel Cormier et al., U.S. Patent No. 5,451,407.

[0018] Methods of treating ACD through the blocking of the elicitation phase after initial exposure to a drug is disclosed, for example, in John McFadden, et al., *J. Invest. Derm.*, Vol. 99, No. 6, pp. 784-786 (December 1992). Tuberculin-induced delayed-type hypersensitivity reaction in human skin was inhibited by topical application of verapamil hydrochloride prior to or concurrent with challenge with tuberculin.

[0019] EP-A-0 247 507 discloses a transdermal delivery system comprising a loop diuretic (e.g. furosemide) as therapeutic agent and a fatty acid alcanolamide.

[0020] US-A-4 897 260 discloses formulations comprising glucocorticoid carboxylic acid esters which are incorporated into percutaneous drug delivery devices for suppressing cutaneous delayed hypersensitivity.

[0021] Also, Richard L. Gallo, et al., *Arch. Dermatol.*, Vol. 125, pp. 502-506 (April 1989) discloses the administration of the diuretic amiloride hydrochloride as a topical anti-inflammatory agent in the treatment of ACD, particularly mice sensitized with 2,4,6-trinitrobenzene.

[0022] As disclosed in commonly assigned U.S. Serial No. 08/198,003 filed February 17, 1994, and references cited therein, irradiation of skin with ultraviolet light B (UVB) is known to be immunosuppressive. These UVB effects are thought to be mediated, in part, by the UVB-induced isomerization of trans-urocanic acid (trans-UCA), a molecule which makes up about 0.5% of the total dry weight in the upper layers of human epidermis, to cis-urocanic acid (cis-UCA). Cis-UCA is known to have various immunosuppressive actions in vivo in a number of experimental systems and is believed to act through histamine-like receptors in the skin. More recently, it has been shown that the UVB impairment of the induction phase of allergic contact dermatitis to epicutaneously applied haptens in certain mouse strains depended on the participation of the cytokine, tumor necrosis factor- α (TNF α). It has been suggested that local release of TNF α may inhibit sensitization by trapping epidermal Langerhans cells and preventing them from reaching the draining lymph node where they activate T cells.

[0023] As further disclosed in U.S. Serial No. 08/198,003, mast cell degranulators such as cis-urocanic acid are effective for preventing or inhibiting the skin sensitizing effect of a transdermally administered therapeutic agent.

[0024] Despite these efforts and the knowledge gained regarding the cause of ACD, there remains a need to develop compositions which effectively prevent the onset of ACD or reduce the adverse effects of ACD after the person has been sensitized to an agent, as for example, a transdermally administered agent such as a drug. There is likewise the need to develop compositions which effectively prevent reactions to skin-irritating agents.

[0025] Applicants have gained the knowledge that there is a distinct process step implicated in the immune response associated with allergic contact dermatitis, which when interfered with, results in the prevention and/or treatment of

ACD. This process step referred to herein as cellular signal transduction, is believed responsible for the acquisition of memory by T-lymphocytes, for the cytokine-mediated regulation of antigen presentation and for other cellular processes as well.

[0026] Applicants have also discovered that a particular class of compounds having diuretic properties, referred to herein as high ceiling or loop diuretics alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid achieves significant improvement in the desensitization of a patient's skin and prevents and/or treats inflammation of the skin. As a result, the reaction of the skin to skin-sensitizing agents or skin-irritating agents is better controlled. The present invention therefore provides the use according to claims 1-21 and 24-28 for the prevention and/or treatment of an adverse reaction to the skin, as well as a transdermal delivery system according to claims 22-23.

SUMMARY OF THE INVENTION

[0027] The present invention is generally directed to the use according to claims 1-21 and 24-28 for the prevention or treatment of allergic contact dermatitis (ACD) and transdermal systems. In one aspect of the invention a use is provided for the manufacture of a medicament for preventing or treating an adverse reaction of the skin caused by the presence of skin-sensitizing agents such as therapeutic agents (e.g. drugs) metals, fragrances, cosmetics, textiles, pollen, pesticides, plastics, combinations thereof and the like, or skin-irritating agents such as cleansers, cleaning agents, alkalis, acids, oils and the like. The present invention is also applicable to ACD induced by the transdermal administration of an agent, as for example, a therapeutic agent such as a drug.

[0028] The skin-sensitizing or skin-irritating agents employed in the present invention can be prepared in the form of a composition containing one or more additives including skin permeation enhancers, excipients and the like.

[0029] These adverse skin reaction preventing or treating agents may be administered topically in the form of lotions, creams, sprays and the like, by non-cutaneous routes as well as through the use of transdermal patches. In transdermal applications, the agents may be administered from a single reservoir also containing a therapeutic agent or preferably from a separate reservoir of a transdermal patch.

DETAILED DESCRIPTION OF THE INVENTION

[0030] The present invention is in part directed to the use according to claims 1-21 and 24-28 for preventing the onset of skin sensitization reactions caused by allergic contact dermatitis by treatment before, after or during the induction phase of sensitization and for alleviating this condition once ACD has progressed to the elicitation phase. The employment of the adverse skin reaction preventing or treating agent in the manufacture of a medicament, according to claims 1-21 and 24-28 provides desensitization of the skin to the presence of skin-sensitizing agents as encountered from a variety of sources including transdermal systems before, after or during the transdermal administration of the therapeutic agent.

[0031] Such adverse skin reaction preventing agents provide inhibition of the immune response and specific immune tolerance to the provoking antigen. More specifically, a single administration to the skin of a high ceiling or loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid renders a warm-blooded animal specifically unresponsive to an antigen, a state known as immunological tolerance. Three immunosuppressive agents known to induce immune tolerance are UVB radiation, the cytokine TNF- α and cis-urocanic acid. A number of mechanisms are thought to be responsible for the induction and maintenance of this tolerant state. Regardless of the mechanism, it is well-known that tolerance to an antigen which stimulates a sensitization response can be induced first by presenting the antigen in a tolerogenic form or via a tolerogenic route. The present invention encompasses a method wherein the immune response of an antigen is suppressed and a state of prolonged immunological tolerance is achieved.

[0032] High ceiling or loop diuretics of the type employed in the present invention affect signal transduction. In the renal tubule, these compounds interfere directly with the reabsorption and/or retention of potassium ions by blocking the action of the potassium ion channels in the Loop of Henle. It is believed that these compounds function as potassium ion pump poisons in that they indirectly interfere with the homeostatically regulated ion balance in other cells. The balance of hydrogen, sodium and calcium ions is upset by changing the net flux of intracellular potassium ions. Consequently, all those cellular processes dependent on the maintenance of homeostatically regulated intracellular ions are disrupted. In particular, the process of cellular signal transduction is known to be highly sensitive to changes in the level of intracellular ions, particularly potassium ions.

[0033] In another aspect of the present invention, the agents and compositions containing the same are also effective in preventing and/or treating adverse responses caused by skin-irritating agents such as household and industrial cleansers, organic solvents and the like. These agents are effective in disrupting the inflammatory response by limiting the ability of the skin-irritating agent to elicit the neurologic, vascular and/or cellular phase of inflammation.

[0034] Examples of loop diuretics for use in the present invention include ethacrynic acid, furosemide and bumetanide. Ethacrynic acid is the preferred loop diuretic.

[0035] The mast cell degranulating agents useful in the present invention are preferably selected from the group consisting of: cis-urocanic acid, or an analogue or a metabolite thereof, PUVA, chloroquine, histamine, capsaicin, morphine sulfate, a sodium channel ionophore, a calcium channel ionophore, an inhibitor of Na⁺/K⁺ channel ATPase, quinine, 4-aminopyridine, an anti-human IgE antibody, compound 48/80, substance P, estradiol, somatostatin, clonidine, progesterone, carbachol, and spantide. Some mast cell degranulating agents may, in appropriate concentrations, be therapeutic agents. Such agents include, for example capsaicin and clonidine.

[0036] Preferred cis-urocanic acid analogues for use in the present invention include, but are not limited to: (a) a cis or trans isomer of 1-furanacrylic acid; (b) a cis or trans isomer of 2-pyrrole acrylic acid; (c) a cis or trans isomer of 2-thiopheneacrylic acid; and (d) dihydrourocanic acid.

[0037] Preferred cis-urocanic acid metabolites for use in the present invention include, but are not limited to: (a) histamine; (b) N¹-methylhistamine; (c) N¹-methylhistidine; (d) histidine; (e) imidazolepyruvic acid; (f) N³-methylhistidine; (g) imidazoleacetic acid; (h) hydantoin 5-propionic acid; and (i) imidazolonepropionic acid.

[0038] Glucocorticosteroids for use in the present invention include, for example, (a) hydrocortisone and analogs thereof, (b) beclomethasone, (c) betamethasone and analogs thereof, (d) clobetasol and analogs thereof, (e) desonide, (f) dexamethasone, (g) fluocinonide, (h) prednisone, and (i) triamcinolone. Hydrocortisone is the preferred glucocorticosteroid.

[0039] The adverse skin reaction preventing or treating agents according to claims 1-28 are useful for preventing or treating skin sensitization or inflammation produced by a variety of skin-sensitizing agents such as, for example, a drug selected from, but not limited to, the following group: (a) an angiotensin converting enzyme inhibitor; (b) a beta adrenergic receptor blocker; (c) an anti-hypertensive drug other than an angiotensin converting enzyme inhibitor or a beta adrenergic receptor blocker; (d) an anti-histamine; (e) an anti-asthmatic; (f) a non-steroidal anti-inflammatory drug; (g) a central nervous system active drug; (h) a weight control drug; (i) an anticoagulant; (j) a potassium control drug; (k) an immunomodulatory drug; (l) a decongestant; and (m) proteins and peptides such as insulin and thyrotropin-releasing hormone.

[0040] The therapeutic agents include all of the major therapeutic areas, including, but not limited to: anti-infectives, such as antibiotics and antivirals; analgesics and analgesic combinations (such as capsaicin); anorexics; antiarthritics; anti-asthmatics (such as albuterol, metaproterenol, ketotifen and terbutaline); anticoagulants (such as urokinase); anticonvulsants; antidepressants; anti-diabetics; antidiarrheals; antihistamines (such as chlorpheniramine and diphenhydramine); anti-inflammatory agents (such as ketoprofen, prostaglandins, flurbiprofen, diclofenac, indomethacin, piroxicam and ibuprofen); antimigraine agents; anti-motion sickness preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics, including gastrointestinal and urinary; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular agents, including angiotensin converting enzyme inhibitors (such as captopril and fosinopril); beta blockers (such as nadolol, timolol, propranolol and alprenolol); antiarrhythmics; antihypertensives (such as clonidine); vasodilators, including general, coronary, peripheral and cerebral; central nervous acting agents (such as fluphenazine, trifluoperazine, haloperidol, Xanax®, Librium®, Valium®); cough and cold preparations; decongestants; diagnostics; hormones; hypnotics; muscle relaxants; parasympatholytics; parasympathomimetics; psychostimulants; sedatives; weight control and appetite suppressive drugs (such as mazin-dol) and tranquilizers.

[0041] The adverse skin reaction preventing or treating agents according to claims 1-28 are also useful for preventing or treating skin irritation produced by a variety of skin-irritating agents as previously described including but not limited to household and industrial cleansers, water, organic solvents, oxidizing and/or reducing agents, alkalis, acids, oils, plant matter, animal matter and the like.

[0042] The present invention further provides an article useful for preventing or treating the skin sensitizing or inflammatory effect of a component of a transdermal drug delivery system, where the component is either a drug, a skin permeation enhancer or a combination of the two and the like, the article comprising:

(a) a transdermal delivery system comprising a therapeutic agent (e.g. a drug) of interest; and

(b) an effective amount of at least one high ceiling or loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

[0043] The adverse skin reaction preventing or treating agents can also be administered in a transdermal or a controlled-release device. Examples of transdermal devices and delivery systems which may be used are disclosed in Bodde, H.E. et al., Crit. Rev. Ther. Drug Carrier Syst. 6:87-115 (1989); and in U.S. Patents No. 3,598,122, 3,598,123, 4,286,592, 4,314,557, 4,379,454, 4,559,222, 4,573,995).

[0044] The delivery system may include a first transdermal device comprising a matrix for placing the adverse skin reaction preventing or treating agents in transmitting relationship to the skin. A second transdermal device may be

used to place the therapeutic agent in transmitting relationship to the skin after the adverse reaction preventing or treating agent has been transdermally administered to the skin. The first and second transdermal devices may be incorporated into a single transdermal patch.

[0045] The adverse skin reaction preventing or treating agents are administered by themselves or, in transdermal systems in combination with a therapeutic agent of interest. These agents may be administered topically or non-cutaneously such as intradermally, intravenously, intramuscularly, orally or intraperitoneally. The agents of the present invention can be incorporated into a pharmaceutically acceptable composition for topical application to the skin in the form of lotions, creams gels and the like. Useful carriers for the preparations of such compositions include water, ethanol, gels and the like.

[0046] The precise formulation of the transdermally administered therapeutic agent (e.g. a drug) and the adverse skin reaction preventing or treating agents of the present invention can be designed to deliver the drug and the agents at the desired fluxes and can be in numerous forms, including, without limitation, ointments, gels and creams. Aqueous formulations, in particular gels, typically comprise water and from about 1 to 2.5% (w/w) of a gelling agent such as hydroxyethylcellulose or hydroxypropylmethylcellulose (HPMC). Typical non-aqueous gels comprise silicone fluid or mineral oil. The mineral oil may also have from about 1 to 2% (w/w) of a gelling agent such as colloidal silicon dioxide. The suitability of a particular gel composition depends on the compatibility of its constituents with the drug (with or without a permeation enhancer) and the adverse skin reaction preventing or treating agents.

[0047] The agents of the present invention may be delivered to the skin alone to prevent skin-sensitization and/or skin irritation or prior to the administration of the therapeutic drug or drugs. Such prior administration can be via transdermal application using a device as described above, via topical application, intracutaneous injection, and the like.

[0048] The agents may also be delivered by another non-cutaneous route and method of delivery, either concurrently with, or prior to, the transdermal administration of the therapeutic drug.

[0049] The composition containing the adverse skin reaction preventing or treating agent according to claim 1-28 is preferably in the form of a lotion, cream or other readily applied topical formulation.

[0050] The dosage of the adverse skin reaction preventing or treating agents administered will be dependent upon the agent, the age, health, and weight of the recipient, kind of concurrent treatment, if any, and frequency of treatment.

[0051] For transdermal administration, typical effective dosages of the agents to prevent and/or treat ACD by a sensitizing drug will depend on their permeation through human skin, and are a function of the physical properties of the permeant, including the partition coefficient of the permeant between solvent and skin, molecular weight and melting point. In general, the maximum flux that can be obtained from any permeant occurs from saturated solutions. Equations have been derived that predict accurately the maximum flux given the partition coefficient, molecular weight and melting point of the permeant as described in, for example, "TREATISE ON CONTROLLED DRUG DELIVERY", A. Kydonieus, ed., Marcel Dekker, Inc., New York, 1991, in particular, p. 370, equations 3a and 4a and p. 34, Figure 2. For example, for the transdermal delivery of the loop diuretics alone or in combination with the mast cell degranulators including the preferred agents, ethacrynic acid and cis-urocanic acid, the expected maximum flux that can be delivered locally to skin is in the range of from about 1 to 50 $\mu\text{g}/\text{cm}^2/\text{hr}$. For transdermal delivery of glucocorticosteroids, including the preferred agent hydrocortisone, the expected maximum flux that can be delivered locally to the skin is in the range of from about 0.005 to 5 $\mu\text{g}/\text{cm}^2/\text{hr}$.

[0052] These values are dependent, for example on varying skin age, skin type and skin condition. The preferred range for the maximum flux for ethacrynic acid plus cis-urocanic acid is from about 5 to 25 $\mu\text{g}/\text{cm}^2/\text{hr}$. For the administration of hydrocortisone the preferred range for the maximum flux is from about 0.01 to 1.0 $\mu\text{g}/\text{cm}^2/\text{hr}$. Accordingly, as will be understood by those skilled in the art, the delivery of a particular agent, is controlled by the percent saturation of that agent in the chosen vehicle.

[0053] The amount of the loop diuretic agent, mast degranulator or glucocorticosteroid which can be delivered to prevent or treat ACD will vary from patient to patient. For example, the amount of the loop diuretic (e.g. ethacrynic acid) delivered from a gel formulation (2.5% HPMC in 75% ethanol) is from about 0.1 to 10% by weight, and preferably from about 0.25% to 2.0% by weight. The amount of the mast cell degranulator (e.g. cis-urocanic acid), which is preferably employed from the same gel formulation in the present invention is in the range of from about 0.1 to 20% by weight, preferably from about 1 to 10% by weight. The amount of glucocorticosteroid (e.g. hydrocortisone) which is preferably employed from the same gel formulation in the present invention is in the range of from about 0.05% to 5% by weight.

[0054] For administration of the adverse skin reaction preventing agents to prevent or treat skin irritation, the dosage will vary. For example for topical application, the preferred agents are loop diuretics alone (e.g. ethacrynic acid) or in combination with a mast cell degranulator (e.g. cis-urocanic acid). In general, the amount of the loop diuretic (e.g. ethacrynic acid) is from about 0.1 to 2.0 percent by weight, preferably from about 0.25 to 1.0 percent by weight based on the total weight of the composition.

[0055] The amount of the mast cell-degranulator (e.g. cis-urocanic acid) is typically from about 1.0 to 20 percent by weight, preferably from about 2.0 to 10 percent by weight based on the total weight of the composition.

[0056] The amount of glucocorticosteroid for prevention or treatment of skin irritation is from about 0.1 to 5.0 percent by weight, preferably from about 0.5 to 2.0 percent by weight.

Example 1

Ethacrynic Acid as A Counter Sensitizer to DNCB

[0057] A 0.5% (w/v) solution of ethacrynic acid was prepared in a gel formulation (2.5% HPMC in 75% ethanol). The same gel formulation served as a negative control. For sensitization, a 1% (w/v) solution of dinitrochlorobenzene (DNCB) was prepared in acetone.

[0058] Twenty-four (24) Balb/c mice had their abdominal skin shaved. The mice were divided into three equal groups. The first group acted as a negative control and received on day 0 an application of 0.2 mL of hydroxypropylmethylcellulose (HPMC) on their exposed abdominal skin. The second group acted as a positive control by receiving on day 0, 0.2 mL of HPMC gel on exposed abdominal skin. The third group of mice was treated with 0.2 mL of HPMC gel containing ethacrynic acid on day 0.

[0059] Twenty-four (24) hours later, the mice in Groups II and III received 10 μ L of 1% DNCB solution over the skin area pretreated with gel, while the mice in Group I received 10 μ L of acetone. All three groups were challenged on the right ear with 20 μ L of 1% DNCB in acetone five (5) days after sensitization.

[0060] Adverse reaction to the challenge with DNCB was determined by measuring the thickness of the mice ears before and after challenge to determine the amount of swelling, and then comparing the degree of swelling for mice treated in accordance with the invention (Group III) with Groups I and Groups II. The results are shown in Table I.

TABLE I

TREATMENT	EAR THICKNESS (MM X 10 ⁻³)	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP I			
NONE (HPMC GEL)			
24 HOURS	238 \pm 5	-	-
48 HOURS	243 \pm 7	-	-
GROUP II			
DNCB ONLY (100 μ g)			
24 HOURS	318 \pm 33	80.0	-
48 HOURS	312 \pm 22	69.0	-
GROUP III			
ETHACRYNIC ACID 1 MG (1N HPMC GEL) (PRE ONLY) + DNCB (100 μ g)			
24 HOURS	281 \pm 26	42	50
48 HOURS	282 \pm 17	39	47

[0061] As shown in Table I, the Group II mice exhibited significant ear swelling when sensitized to DNCB. The loop diuretic, ethacrynic acid alone constituting an adverse skin reaction preventing agent when administered prophylactically limits adverse reactions induced by sensitization with DNCB.

Example 2

Furosemide as A Counter Sensitizer to DNCB

[0062] The procedures of Example 1 were repeated except that the adverse skin reaction preventing or treating agent was a 1.0% (w/v) formulation of furosemide. The results are shown in Table II.

TABLE II

TREATMENT	EAR THICKNESS (MM x 10 ⁻³)	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
GROUP I			
NONE (HPMC GEL) 24 HOURS	236 ± 4	- -	- -
GROUP II			
DNCB ONLY (100 µg) 24 HOURS	299 ± 35	63	-
GROUP III			
FUROSEMIDE 2 MG (1N HPMC GEL) + DNCB (100 µg) 24 HOURS	288 ± 18	52	17

[0063] As shown in Table II, the Group II mice exhibited significant ear swelling when sensitized to DNCB. Furosemide constituting an adverse skin reaction preventing agent when administered prophylactically limits adverse skin reactions induced by sensitization to DNCB.

Example 3

Ethacrynic and Cis Urocanic Acid as Counter Sensitizers to DNCB

[0064] The procedures of Example 1 were repeated except that the adverse skin reaction preventing or treating agent was a combination of a 2.5% (w/v) solution of cis-urocanic acid and a 0.25 % (w/v) of ethacrynic acid solution prepared in the above HPMC gel. The results are shown in Table III.

TABLE III

TREATMENT	EAR THICKNESS (MM X 10 ⁻³)	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP I			
(HPMC GEL) 24 HOURS	241 ± 4	-	-
48 HOURS	243 ± 5	-	-
GROUP II			
DNCB ONLY (100 µg) 24 HOURS	318 ± 24	77.0	-
48 HOURS	326 ± 23	83.0	-
GROUP III			
(CIS UROCANIC ACID 10 MG + ETHACRYNIC ACID 1 MG IN HPMC GEL) (PRE ONLY) + DNCB (100 µg) 24 HOURS	245 ± 13	4	95
48 HOURS	264 ± 23	21	74

[0065] As shown in Table III, the Group II mice exhibited significant ear swelling when sensitized with DNCB. The combination of cis-urocanic acid and ethacrynic acid constituting an adverse skin reaction preventing or treating agent in accordance with the present invention suppressed adverse reactions induced by sensitization with DNCB.

Example 4

Ethacrynic Acid and Hydrocortisone as Counter Sensitizers to DNCB

- [0066] The procedures of Example 1 were repeated except that the adverse skin reaction preventing or treating agent was a combination of a 1% (w/v) solution of hydrocortisone, and a 0.25% (w/v) solution of ethacrynic acid, prepared in the above gel formulation. The results are shown in Table IV.

TABLE IV

TREATMENT	EAR THICKNESS (MM x 10 ⁻³)	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
NONE (HPMC GEL)			
24 HOURS	250 ± 5	-	-
48 HOURS	245 ± 7	-	-
DNCB ONLY (100 µg)			
24 HOURS	371 ± 21	121	-
48 HOURS	371 ± 30	126	-
(Hydrocortisone 2 mg + Ethacrynic Acid 0.5 mg) (in HPMC GEL)	318 ± 42	68	44.1
(PRE ONLY) + DNCB (100 µg)	293 ± 26	48	62.1
24 HOURS			
48 HOURS			

- [0067] As shown in Table IV, the Group II mice showed significant ear swelling when sensitized with DNCB. The combination of hydrocortisone and ethacrynic acid constituting an adverse skin reaction preventing or treating agent in accordance with the present invention suppressed adverse reactions induced by sensitization with DNCB.

Example 5

Ethacrynic Acid as A Counter Sensitizer to Albuterol

- [0068] Forty (40) CBA/J female mice were obtained from Jackson Labs. A 0.5% (w/v) solution of ethacrynic acid was prepared in a gel formulation (2.5% HPMC in 75% ethanol). A 5% (w/v) solution and a 1% (w/v) solution of albuterol were also prepared. In addition a 2.5% HPMC solution was prepared as a placebo.

- [0069] The mice were shaved on their back. Positive control mice (10) received the placebo and the 5% albuterol solution on alternating days for three weeks. The experimental mice (10) received the ethacrynic acid solution and the 5% albuterol solution on alternating days for three weeks.

- [0070] A negative control group of mice (20) received the placebo gel on each day for three weeks.

- [0071] Five days after the last application each group of mice were challenged on the right ear with the 1% albuterol solution and on the left ear with the placebo gel. The thickness of the ears was measured after 24, 48, and 72 hours. The results are shown in Table V.

TABLE V

TREATMENT	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL)		
24 HOURS	-	-
48 HOURS	-	-
72 HOURS	-	-

TABLE V (continued)

TREATMENT	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP II		
ALBUTEROL ONLY		
24 HOURS	52	-
48 HOURS	83	-
72 HOURS	57	-
GROUP III		
ETHACRYNIC ACID + ALBUTEROL		
24 HOURS	0	100
48 HOURS	0	100
72 HOURS	17	79

[0072] As shown in Table V, the Group II mice exhibited significant ear swelling when sensitized to albuterol. Ethacrynic acid alone constituting an adverse skin reaction preventing or treating agent limited adverse reactions induced by sensitization with albuterol.

Example 6

Ethacrynic Acid as A Counter Sensitizer to Chlorpheniramine

[0073] The procedures of Example 5 were repeated except that the mice were sensitized with chlorpheniramine in an amount of 5% (w/v). The results are shown in Table VI.

TABLE VI

TREATMENT	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL)		
24 HOURS	-	-
48 HOURS	-	-
72 HOURS	-	-
GROUP II		
CHLORPHENIRAMINE ONLY		
24 HOURS	56	-
48 HOURS	53	-
72 HOURS	28	-
GROUP III		
ETHACRYNIC ACID + CHLORPHENIRAMINE		
24 HOURS	0	100
48 HOURS	0	100
72 HOURS	0	100

[0074] As shown in Table VI, the Group II mice exhibited significant ear swelling when sensitized to chlorpheniramine. Ethacrynic acid alone constituting an adverse skin reaction preventing or treating agent limited adverse reactions induced by sensitization with chlorpheniramine.

Example 7

Ethacrynic Acid as A Counter Sensitizer to Clonidine

- 5 [0075] The procedures of Example 5 were repeated except that the mice were sensitized with clonidine in an amount of 5% (w/v). The results are shown in Table VII.

TABLE VII

TREATMENT	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL)		
24 HOURS	-	-
48 HOURS	-	-
72 HOURS	-	-
GROUP II		
CLONIDINE ONLY		
24 HOURS	32	-
48 HOURS	52	-
72 HOURS	22	-
GROUP III		
ETHACRYNIC ACID + CLONIDINE		
24 HOURS	0	100
48 HOURS	0	100
72 HOURS	7	67

30 [0076] As shown in Table VII, the Group II mice exhibited significant ear swelling when sensitized to clonidine. Ethacrynic acid alone constituting an adverse skin reaction preventing or treating agent limited adverse reactions induced by sensitization with clonidine.

35 Example 8

Ethacrynic Acid as A Counter Sensitizer to Nadolol

- 40 [0077] The procedures of Example 5 were repeated except that the skin sensitizing agent was nadolol in an amount of 5% (w/v). The results are shown in Table VIII.

TABLE VIII

TREATMENT	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL)		
24 HOURS	-	-
48 HOURS	-	-
72 HOURS	-	-
GROUP II		
NADOLOL ONLY		
24 HOURS	52	-
48 HOURS	53	-
72 HOURS	63	-

TABLE VIII (continued)

TREATMENT	EAR SWELLING (MM x 10 ⁻³)	% SUPPRESSION
GROUP III		
ETHACRYNIC ACID + NADOLOL		
24 HOURS	0	100
48 HOURS	0	100
72 HOURS	20	67

[0078] As shown in Table VIII, the Group II mice exhibited significant ear swelling when sensitized to nadolol. Ethacrynic acid alone constituting an adverse skin reaction preventing or treating agent limited adverse reactions induced by sensitization with nadolol.

Example 9

Ethacrynic Acid as A Counter Sensitizer to Mice Already Sensitized to Oxazolone

[0079] In this example, the question was considered as to whether ethacrynic acid could prevent an adverse reaction after the mice were sensitized by a primary exposure to oxazolone and then treated immediately after challenge with the sensitizing agent.

[0080] Thirty (30) Balb/c female mice were obtained from Sprague Dawley Labs. A 1.0% (w/v) solution of ethacrynic acid was prepared in a gel formulation (1.0% HPMC in 75% ethanol). A 1% (w/v) solution of oxazolone in acetone was also prepared. In addition a 1.0% HPMC solution was prepared as a placebo.

[0081] The mice were shaved on their back and divided into three groups. Group II (10 mice) acted as a positive control and received 10 μ L of the oxazolone solution. Group III (10 mice) were designated the experimental mice and received 10 μ L of the oxazolone solution. Group I (10 mice) acted as a negative control group and received 10 μ L of acetone.

[0082] Five days after the last application, Groups I, II and III mice received 20 μ L of the oxazolone solution to the right ear. Five minutes after the challenge, 100 μ L of the placebo was applied to the right ears of Groups I and II and 100 μ L of the

Example 8

Ethacrynic Acid as A Counter Sensitizer to Nadolol

[0083] The procedures of Example 5 were repeated except that the skin sensitizing agent was nadolol in an amount of 5% (w/v). The results are shown in Table VIII.

TABLE VIII

TREATMENT	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL)		
24 HOURS	-	-
48 HOURS	-	-
72 HOURS	-	-
GROUP II		
NADOLOL ONLY		
24 HOURS	52	-
48 HOURS	53	-
72 HOURS	63	-

TABLE VIII (continued)

TREATMENT	EAR SWELLING (MM X 10 ⁻³)	% SUPPRESSION
GROUP III		
ETHACRYNIC ACID + NADOLOL		
24 HOURS	0	100
48 HOURS	0	100
72 HOURS	20	67

[0084] As shown in Table VIII, the Group II mice exhibited significant ear swelling when sensitized to nadolol. Ethacrynic acid alone constituting an adverse skin reaction preventing or treating agent limited adverse reactions induced by sensitization with nadolol.

Example 10

Ethacrynic Acid Inhibits Irritation Induced by Lactic Acid

[0085] Thirty (30) Balb/c female mice were obtained from Sprague Dawley Labs. A 1.0% (w/v) solution of ethacrynic acid was prepared in a gel formulation (2.5% HPMC in 75% ethanol). A 25% (w/v) solution of lactic acid (sufficient to elicit a strong irritant response), was also prepared. In addition a 1.0% HPMC solution was prepared as a placebo.

[0086] The mice were shaved on their back. Group I (10 mice) received the placebo only. Positive control mice (10) designated as Group II received the lactic acid solution to the right ear and five minutes later 50-100 μ L of the placebo. The experimental mice (10) (Group III) received the ethacrynic acid solution to the right ear followed five minutes later by the lactic acid solution.

[0087] The thickness of the ears was measured after 2 hours when maximum redness and swelling from lactic acid were observed. The results are shown in Table X.

TABLE X

TREATMENT	EAR THICKNESS (MM x 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL) 2 HOURS	240 \pm 9	-
GROUP II		
LACTIC ACID ONLY 2 HOURS	276 \pm 23	-
GROUP III		
ETHACRYNIC ACID + LACTIC ACID 2 HOURS	243 \pm 12	99

[0088] As shown in Table X, the Group II mice exhibited significant ear swelling when contacted with lactic acid. Ethacrynic acid constituting an adverse skin reaction preventing or treating agent suppressed inflammation induced by contact with lactic acid.

Example 11

Ethacrynic Acid Inhibits Irritation Induced by Capsaicin

[0089] The procedures of Example 10 were repeated except that lactic acid was replaced by capsaicin in an amount of 5% (w/v) in a 1% HPMC gel. The results are shown in Table XI.

TABLE XI

TREATMENT	EAR THICKNESS (MM X 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL) 2 HOURS	269 ± 11	-
GROUP II		
CAPSAICIN ONLY 2 HOURS	338 ± 23	-
GROUP III		
ETHACRYNIC ACID + CAPSAICIN 2 HOURS	298 ± 19	58.6

[0090] As shown in Table XI, the Group II mice exhibited significant ear swelling when contacted with capsaicin. Ethacrynic acid constituting an adverse skin reaction preventing or treating agent suppressed inflammation induced by capsaicin.

Example 12

Ethacrynic Acid Inhibits Irritation Induced By Arachidonic Acid

[0091] The procedures of Example 10 were repeated except that lactic acid was replaced with arachidonic acid in an amount of 5% (w/v) in a 1% HPMC gel. The results are shown in Table XII.

TABLE XII

TREATMENT	EAR THICKNESS (MM X 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL) 2 HOURS	241 ± 9	-
GROUP II		
ARACHIDONIC ACID ONLY 2 HOURS	327 ± 13	-
GROUP III		
ETHACRYNIC ACID + ARACHIDONIC ACID 2 HOURS	289 ± 22	45

[0092] As shown in Table XII, the Group II mice exhibited significant ear swelling when contacted with arachidonic acid. Ethacrynic acid constituting an adverse skin reaction preventing or treating agent suppressed inflammation induced by contact with arachidonic acid.

Example 13

Ethacrynic Acid Inhibits Irritation Induced By PMA

[0093] The procedures of Example 10 were repeated except that lactic acid was replaced with phorbol 12-myristate 13-acetate (PMA) in an amount of 0.1% (w/v) in a 1% HPMC gel. The results are shown in Table XIII.

TABLE XIII

TREATMENT	EAR THICKNESS (MM X 10 ⁻³)	% SUPPRESSION
GROUP I		
NONE (HPMC GEL) 2 HOURS	226 ± 4	-
GROUP II		
PMA ONLY 2 HOURS	265 ± 14	-
GROUP III		
ETHACRYNIC ACID + PMA 2 HOURS	226 ± 9	100

[0094] As shown in Table XIII, the Group II mice exhibited significant ear swelling when contacted with phorbol 12-myristate 13-acetate. Ethacrynic acid constituting an adverse skin reaction preventing or treating agent suppressed inflammation induced by contact with PMA.

Claims

1. Use of an effective amount of an adverse skin reaction preventing or treating agent comprising at least one loop diuretic alone or in combination with at least one mast cell degranulator or glucocorticosteroid in the manufacture of a medicament which is administrable to a warm-blooded animal for preventing or treating an adverse reaction of the skin of said warm-blooded animal to the presence of at least one skin-sensitizing agent or skin-irritating agent.
2. The use of claim 1 characterised in that the skin-sensitizing agent is selected from the group consisting of therapeutic agents, metals, fragrances, cosmetics, textiles, pollen, pesticides, plastics and combinations thereof.
3. The use of claim 1 characterised in that the skin-irritating agent is selected from the group consisting of water, cleansers, alkalis, acids, oils, organic solvents, oxidizing agents, reducing agents, plant matter, animal matter and combinations thereof.
4. The use of claim 1 characterised in that said adverse skin reaction preventing or treating agent is administered topically to the skin.
5. The use of claim 4 characterised in that said adverse skin reaction preventing or treating agent is administered transdermally.
6. The use of claim 5 characterised in that the skin-sensitizing agent is a therapeutic agent, and said adverse skin reaction preventing or treating agent and the therapeutic agent is administered from a transdermal patch.
7. The use of claim 1 characterised in that the loop diuretic is selected from the group consisting of ethacrynic acid, furosemide and bumetanide.
8. The use of claim 7 characterised in that the loop diuretic is ethacrynic acid.
9. The use of claim 1 characterised in that the mast cell degranulator is selected from the group consisting of cis-urocanic acid, analogs and metabolites thereof, PUVA, chloroquine, histamine, capsaicin, morphine sulfate, a sodium channel ionophore, a calcium channel ionophore, an inhibitor of Na⁺/K⁺ channel ATPase, quinine, 4-amino pyridine, anti-human IgE antibody, compound 40/80, substance P, estradiol, somatostatin, carbachol, progesterone, spantide, and clonidine.
10. The use of claim 1 characterised in that the analogs of cis-urocanic acid are selected from the group consisting

of 1-furanacrylic acid, 2-pyrrole acrylic acid, 2-thiophenacrylic acid, dihydrourocanic acid and trans-urocanic acid.

11. The use of claim 9 characterised in that the mast cell degranulator is cis-urocanic acid.
- 5 12. The use of claim 1 characterised in that the glucocorticosteroid is selected from the group consisting of hydrocortisone and analogs thereof, beclomethasone, betamethasone and analogs thereof, clobetasol and analogs thereof, desonide, dexamethasone, fluocinonide, prednisone, and triamcinolone.
- 10 13. The use of claim 12 characterised in that the glucocorticosteroid is hydrocortisone.
14. The use of claim 5 characterised in that maximum flux of the loop diuretic alone or in combination with the mast cell degranulator is from about 1 to 50 $\mu\text{g}/\text{cm}^2/\text{hr}$.
- 15 15. The use of claim 14 characterised in that the maximum flux of the loop diuretic alone or in combination with the mast cell degranulator is from about 5 to 25 $\mu\text{g}/\text{cm}^2/\text{hr}$.
16. The use of claim 5 characterised in that the maximum flux of the glucocorticosteroid is from about 0.005 to 5 $\mu\text{g}/\text{cm}^2/\text{hr}$.
- 20 17. The use of claim 16 characterised in that the maximum flux of the glucocorticosteroid is from about 0.1 to 1.0 $\mu\text{g}/\text{cm}^2/\text{hr}$.
18. The use of claim 1 characterised in that an amount of said adverse skin reaction preventing or treating agent is administered to the warm blooded animal sufficient to treat or prevent allergic contact dermatitis caused by a skin-sensitizing agent in the form of a gel, said amount of the loop diuretic being from about 0.1 to 10% weight, the amount of the mast cell degranulator being from about 0 to 20% by weight and the amount of the glucocorticosteroid being from about 0 to 5% by weight.
- 25 19. The use of claim 18 characterised in that the amount of the loop diuretic is from about 0.25 to 2.0% by weight and the amount of the mast cell degranulator is from about 1 to 10% by weight.
- 30 20. The use of claim 1 characterised in that an amount of said adverse skin reaction preventing or treating agent is administered to the warm blooded animal sufficient to treat or prevent allergic contact dermatitis caused by a skin-sensitizing agent in the form of a gel, said amount of the loop diuretic being from about 0.1 to 2.0% by weight, the amount of the mast cell degranulator being from about 0 to 20% by weight and the amount of the glucocorticosteroid being from about 0 to 5 % by weight.
- 35 21. The use of claim 20 characterised in that the amount of the loop diuretic is from about 0.25 to 1.0% weight, the amount of the mast cell degranulator is from about 2.0 to 10% by weight and the amount of the glucocorticosteroid is from about 0.5 to 2.0% weight.
- 40 22. A transdermal delivery system for transdermally administering an effective amount of an adverse skin reaction preventing or treating agent comprising a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid, said system comprising:
 - 45 (a) a first transdermal device comprising a matrix for placing the adverse skin reaction preventing or treating agent in transmitting relationship to the skin; and
 - (b) a second transdermal agent comprising a matrix for placing a therapeutic agent in transmitting relationship to the skin after the adverse skin reaction preventing or treating agent has been transdermally administered to the skin from the first transdermal device.
- 50 23. The transdermal delivery system of claim 22 characterised in that the first and second transdermal devices are contained within a single transdermal patch.
- 55 24. Use of an effective amount of an adverse skin reaction preventing agent comprising a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid in the manufacture of a medicament which is transdermally administrable to a warm-blooded animal before, after or during the administration of a therapeutic agent, for preventing or treating an adverse reaction of the skin.

25. The use of claim 24 characterised in that the loop diuretic is selected from the group consisting of ethacrynic acid, furosemide and bumetanide.
26. The use of claim 24 characterised in that the mast cell degranulator is selected from the group consisting of cis-urocanic acid, analogs and metabolites thereof, PUVA, chloroquine, histamine, capsaicin, morphine sulfate, a sodium channel ionophore, a calcium channel ionophore, an inhibitor of Na⁺/K⁺ channel ATPase, quinine, 4-amino pyridine, anti-human IgE antibody, compound 48/80, substance P, estradiol, somatastatin, carbachol, progesterone, spantide, and clonide.
27. The use of claim 26 characterised in that the analogs of cis-urocanic acid are selected from the group consisting of 1- furanacrylic acid, 2-pyrrole acrylic acid, 2-thiophenacrylic acid, dihydrourocanic acid and trans-urocanic acid.
28. The use of claim 24 characterised in that the glucocorticosteroid is selected from the group consisting of hydrocortisone and analogs thereof, beclomethasone, betamethasone and analogs thereof, clobetasol and analogs thereof, desonide, dexamethasone, flucinonide, prednisone, and triamcinolone.

Patentansprüche

1. Verwendung einer wirksamen Menge eines Mittels zur Verhinderung oder Behandlung einer schädlichen Nebenwirkung an der Haut umfassend mindestens ein Schleifendiuretikum allein oder in Kombination mit mindestens einem Mastzelldegranulator oder Glucocorticosteroid bei der Herstellung eines Arzneimittels, das an einen Warmblüter verabreicht werden kann, zur Verhinderung oder Behandlung einer schädlichen Nebenwirkung an der Haut bei diesem Warmblüter in Gegenwart von mindestens einem hautsensibilisierenden Mittel oder hautreizenden Mittel.
2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das hautsensibilisierende Mittel ausgewählt ist aus therapeutischen Mitteln, Metallen, Duftstoffen, Kosmetika, Textilien, Pollen, Pestiziden, Kunststoffen und Kombinationen davon.
3. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das hautreizende Mittel ausgewählt ist aus Wasser, Reinigungsmitteln, Alkalien, Säuren, Ölen, organischen Lösungsmitteln, oxidierenden Mitteln, reduzierenden Mitteln, Pflanzenmaterial, Tiermaterial und Kombinationen davon.
4. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das Mittel zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut topisch auf die Haut verabreicht wird.
5. Verwendung nach Anspruch 4, dadurch gekennzeichnet, dass das Mittel zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut transdermal verabreicht wird.
6. Verwendung nach Anspruch 5, dadurch gekennzeichnet, dass das hautsensibilisierende Mittel ein therapeutisches Mittel ist, und das Mittel zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut und das therapeutische Mittel über ein transdermales Pflaster verabreicht werden.
7. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das Schleifendiuretikum ausgewählt ist aus Ethacrynsäure, Furosemid und Bumetanid.
8. Verwendung nach Anspruch 7, dadurch gekennzeichnet, dass das Schleifendiuretikum Ethacrynsäure ist.
9. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass der Mastzelldegranulator ausgewählt ist aus cis-Urocansäure, Analoga und Metabolite davon, PUVA, Chloroquin, Histamin, Capsaicin, Morphinsulfat, einem Natriumkanal-ionophor, einem Calciumkanal-ionophor, einem Inhibitor der Na⁺/K⁺-Kanal-ATPase, Chinin, 4-Aminopyridin, anti-human IgE Antikörper, Verbindung 48/80, Substanz P, Estradiol, Somatastatin, Karbachol, Progesteron, Spantid und Clonidin.
10. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass die Analoga von cis-Urocansäure ausgewählt sind aus 1-Furanacrylsäure, 2-Pyrrolacrylsäure, 2-Thiophenacrylsäure, Dihydrourocansäure und trans-Urocansäure.

11. Verwendung nach Anspruch 9, **dadurch gekennzeichnet**, dass der Mastzelldegranulator cis-Urocansäure ist.
12. Verwendung nach Anspruch 1, **dadurch gekennzeichnet**, dass das Glucocorticosteroid ausgewählt ist aus Hydrocortison und Analoga davon, Beclomethason, Betamethason und Analoga davon, Clobetasol und Analoga davon, Desonid, Dexamethason, Fluciclonid, Prednison und Triamcinolon.
13. Verwendung nach Anspruch 12, **dadurch gekennzeichnet**, dass das Glucocorticosteroid Hydrocortison ist.
14. Verwendung nach Anspruch 5, **dadurch gekennzeichnet**, dass der maximale Fluss des Schleifendiuretikums allein oder in Kombination mit dem Mastzelldegranulator etwa 1 bis 50 µg/cm²/Stunde ist.
15. Verwendung nach Anspruch 14, **dadurch gekennzeichnet**, dass der maximale Fluss des Schleifendiuretikums allein oder in Kombination mit dem Mastzelldegranulator etwa 5 bis 25 µg/cm²/Stunde ist.
16. Verwendung nach Anspruch 5, **dadurch gekennzeichnet**, dass der maximale Fluss des Glucocorticosteroids etwa 0.005 bis 5 µg/cm²/Stunde ist.
17. Verwendung nach Anspruch 16, **dadurch gekennzeichnet**, dass der maximale Fluss des Glucocorticosteroids etwa 0.1 bis 1.0 µg/cm²/Stunde ist.
18. Verwendung nach Anspruch 1, **dadurch gekennzeichnet**, dass eine ausreichende Menge des Mittels zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut an den Warmblüter in Form eines Gels verabreicht wird, um allergische Kontakt-Dermatitis, verursacht durch ein hautsensibilisierendes Mittel zu behandeln oder zu verhindern, wobei die Menge des Schleifendiuretikums etwa 0.1 bis 10 Gew.-%, die Menge des Mastzelldegranulators etwa 0 bis 20 Gew.-% und die Menge des Glucocorticosteroids etwa 0 bis 5 Gew.-% ist.
19. Verwendung nach Anspruch 18, **dadurch gekennzeichnet**, dass die Menge des Schleifendiuretikums etwa 0.25 bis 2.0 Gew.-% und die Menge des Mastzelldegranulators etwa 1 bis 10 Gew.-% ist.
20. Verwendung nach Anspruch 1, **dadurch gekennzeichnet**, dass eine ausreichende Menge des Mittels zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut an den Warmblüter in Form eines Gels verabreicht wird, um allergische Kontakt-Dermatitis, verursacht durch ein hautsensibilisierendes Mittel zu behandeln oder zu verhindern, wobei die Menge des Schleifendiuretikums etwa 0.1 bis 2 Gew.-%, die Menge des Mastzelldegranulators etwa 0 bis 20 Gew.-% und die Menge des Glucocorticosteroids etwa 0 bis 5 Gew.-% ist.
21. Verwendung nach Anspruch 20, **dadurch gekennzeichnet**, dass die Menge des Schleifendiuretikums etwa 0.25 bis 1.0 Gew.-%, die Menge des Mastzelldegranulators etwa 2.0 bis 10 Gew.-% und die Menge des Glucocorticosteroids etwa 0.5 bis 2.0 Gew.-% ist.
22. System zur transdermalen Verabreichung einer wirksamen Menge eines Mittels zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut umfassend ein Schleifendiuretikum allein oder in Kombination mit mindestens einem Mastzelldegranulator oder mindestens einem Glucocorticosteroid, wobei die Einrichtung umfasst:
 - (a) eine erste transdermale Vorrichtung umfassend eine Matrix die das Mittel zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut so lokalisiert, dass es in übertragender Beziehung zur Haut steht; und
 - (b) eine zweite transdermale Vorrichtung umfassend eine Matrix die ein therapeutisches Mittel so lokalisiert, dass es in übertragender Beziehung zur Haut steht, nachdem das Mittel zur Verhinderung oder Behandlung von schädlichen Nebenwirkungen an der Haut transdermal in die Haut mit der ersten transdermalen Vorrichtung verabreicht wurde.
23. System nach Anspruch 22, **dadurch gekennzeichnet**, dass die erste und die zweite transdermale Vorrichtung in einem einzigen transdermalen Pflaster enthalten sind.
24. Verwendung einer wirksamen Menge eines Mittels zur Verhinderung einer schädlichen Nebenwirkung an der Haut umfassend ein Schleifendiuretikum allein oder in Kombination mit mindestens einem Mastzelldegranulator oder mindestens einem Glucocorticosteroid bei der Herstellung eines Arzneimittels, das an einen Warmblüter trans-

dermal verabreicht werden kann, bevor, nach oder während der Verabreichung eines therapeutischen Mittels zur Verhinderung oder Behandlung einer schädlichen Nebenwirkung an der Haut.

25. Verwendung nach Anspruch 24, **dadurch gekennzeichnet**, dass das Schleifendiuretikum ausgewählt ist aus Ethacrynsäure, Furosemid und Bumetanid.
26. Verwendung nach Anspruch 24, **dadurch gekennzeichnet**, dass der Mastzelldegranulator ausgewählt ist aus cis-Urocansäure, Analoga und Metabolite davon, PUVA, Chloroquin, Histamin, Capsaicin, Morphinsulfat, einem Natriumkanalionophor, einem Calciumkanalionophor, einem Inhibitor der Na⁺/K⁺-Kanal-ATPase, Chinin, 4-Aminopyridin, anti-human IgE Antikörper, Verbindung 48/80, Substanz P, Estradiol, Somatostatin, Karbachol, Progesteron, Spantid und Clonidin.
27. Verwendung nach Anspruch 26, **dadurch gekennzeichnet**, dass die Analoga von cis-Urocansäure ausgewählt sind aus 1-Furanacrylsäure, 2-Pyrrolacrylsäure, 2-Thiophenacrylsäure, Dihydrourocansäure und trans-Urocansäure.
28. Verwendung nach Anspruch 24, **dadurch gekennzeichnet**, dass das Glucocorticosteroid ausgewählt ist aus Hydrocortison und Analoga davon, Beclomethason, Betamethason und Analoga davon, Clobetasol und Analoga davon, Desonid, Dexamethason, Fluocinonid, Prednison und Triamcinolon.

Revendications

1. Utilisation d'une quantité efficace d'un agent de prévention ou de traitement d'une réaction cutanée néfaste comprenant au moins un diurétique de l'anse seul ou en combinaison avec au moins un agent de dégranulation des mastocytes ou un glucocorticostéroïde dans la fabrication d'un médicament qui peut être administré à un animal à sang chaud en vue de prévenir ou de traiter une réaction néfaste de la peau dudit animal à sang chaud à la présence d'au moins un agent de sensibilisation cutanée ou un agent d'irritation cutanée.
2. Utilisation selon la revendication 1, **caractérisée en ce que** l'agent de sensibilisation cutanée est choisi parmi le groupe constitué d'agents thérapeutiques, de métaux, de parfums, de cosmétiques, de textiles, de pollen, de pesticides, de matières plastiques et de combinaisons de ceux-ci.
3. Utilisation selon la revendication 1, **caractérisée en ce que** l'agent d'irritation cutanée est choisi parmi le groupe constitué de l'eau, de produits nettoyants, d'alcalis, d'acides, d'huiles, de solvants organiques, d'agents oxydants, d'agents réducteurs, de matières végétales, de matières animales, et de combinaisons de ceux-ci.
4. utilisation selon la revendication 1, **caractérisée en ce que** ledit agent de prévention ou de traitement de réactions cutanées néfastes est administré localement sur la peau.
5. Utilisation selon la revendication 4, **caractérisé en ce que** ledit agent de prévention ou de traitement de réactions cutanées néfastes est administré de façon transdermique.
6. Utilisation selon la revendication 5, **caractérisée en ce que** l'agent de sensibilisation cutanée est un agent thérapeutique, et ledit agent de prévention ou de traitement de réactions cutanées néfastes et l'agent thérapeutique sont administrés à partir d'un timbre transdermique.
7. Utilisation selon la revendication 1, **caractérisée en ce que** le diurétique de l'anse est choisi parmi le groupe constitué de l'acide éthacrynique, du furosémide et du bumétanide.
8. Utilisation selon la revendication 7, **caractérisée en ce que** le diurétique de l'anse est l'acide éthacrynique.
9. Utilisation selon la revendication 1, **caractérisée en ce que** l'agent de dégranulation des mastocytes est choisi parmi le groupe constitué de l'acide cis-urocanique, des analogues et des métabolites de celui-ci, de la PUVA, de la chloroquine, de l'histamine, de la capsaïcine, du sulfate de morphine, d'un ionophore du canal sodique, d'un ionophore du canal calcique, d'un inhibiteur de l'ATPase du canal Na⁺/K⁺, de la quinine, de la 4-amino pyridine, de l'anticorps anti-IgE humaine, du composé 40/80, de la substance P, de l'estradiol, de la somatostatine, du carbachol, de la progestérone, du spantide et de la clonidine.

10. Utilisation selon la revendication 1, **caractérisée en ce que** les analogues de l'acide cis-urocanique sont choisis parmi le groupe constitué de l'acide 1-furane-acrylique, de l'acide 2-pyrole-acrylique, de l'acide 2-thiophène-acrylique, de l'acide dihydro-urocanique et de l'acide trans-urocanique.
- 5 11. Utilisation selon la revendication 9, **caractérisée en ce que** l'agent de dégranulation des mastocytes est l'acide cis-urocanique.
12. Utilisation selon la revendication 1, **caractérisée en ce que** le glucocorticostéroïde est choisi parmi le groupe constitué de l'hydrocortisone et des analogues de celle-ci, de la béclo méthasone, de la bétaméthasone et des
10 analogues de celle-ci, du clobétasol et des analogues de celui-ci, de la désenide, de la dexaméthasone, du fluocinonide, de la prednisone et de la triamcinolone.
13. Utilisation selon la revendication 12, **caractérisée en ce que** le glucocorticostéroïde est l'hydrocortinone.
- 15 14. Utilisation selon la revendication 5, **caractérisée en ce que** le flux maximum du diurétique de l'anse seul ou en combinaison avec l'agent de dégranulation des mastocytes est d'environ 1 à 50 µg/cm²/h.
15. Utilisation selon la revendication 14, **caractérisée en ce que** le flux maximum du diurétique de l'anse seul ou en
20 combinaison avec l'agent de dégranulation des mastocytes est d'environ 5 à 25 µg/cm²/h.
16. Utilisation selon la revendication 5, **caractérisée en ce que** le flux maximum du glucocorticostéroïde est d'environ 0,005 à 5 µg/cm²/h.
17. Utilisation selon la revendication 16, **caractérisée en ce que** le flux maximum du glucocorticostéroïde est d'environ
25 0,1 à 1,0 µg/cm²/h.
18. Utilisation selon la revendication 1, **caractérisée en ce que** la quantité dudit agent de prévention ou de traitement de réactions cutanées néfastes est administrée à l'animal à sang chaud en quantité suffisante pour traiter ou
30 prévenir un eczéma de contact allergique provoqué par un agent de sensibilisation cutanée sous la forme d'un gel, ladite quantité du diurétique de l'anse étant d'environ 0,1 à 10 % en poids, la quantité de l'agent de dégranulation des mastocytes étant d'environ 0 à 20 % en poids et la quantité du glucocorticostéroïde étant d'environ 0 à 5 % en poids.
19. Utilisation selon la revendication 18, **caractérisée en ce que** la quantité du diurétique de l'anse est d'environ 0,25
35 à 2,0 % en poids et la quantité de l'agent de dégranulation des mastocytes est d'environ 1 à 10 % en poids.
20. Utilisation selon la revendication 1, **caractérisée en ce qu'une** quantité dudit agent de prévention ou de traitement de réactions cutanées néfastes est administrée à l'animal à sang chaud en quantité suffisante pour traiter ou
40 prévenir un eczéma de contact allergique provoqué par un agent de sensibilisation cutanée sous la forme d'un gel, ladite quantité du diurétique de l'anse étant d'environ 0,1 à 2,0 % en poids, la quantité de l'agent de dégranulation des mastocytes étant d'environ 0 à 20 % en poids et la quantité du glucocorticostéroïde étant d'environ 0 à 5 % en poids.
21. Utilisation selon la revendication 20, **caractérisée en ce que** la quantité du diurétique de l'anse est d'environ 0,25
45 à 1,0 % en poids, la quantité de l'agent de dégranulation des mastocytes est d'environ 2,0 à 10 % en poids et la quantité du glucocorticostéroïde est d'environ 0,5 à 2,0 % en poids.
22. Système de délivrance transdermique destiné à administrer de façon transdermique une quantité efficace d'un agent de prévention ou de traitement de réactions cutanées néfastes comprenant un diurétique de l'anse seul ou
50 en combinaison avec au moins un agent de dégranulation des mastocytes ou au moins un glucocorticostéroïde, ledit système comprenant :
 - (a) un premier dispositif transdermique comprenant une matrice destinée à placer l'agent de prévention ou de traitement de réactions cutanées néfastes en relation de transmission vers la peau, et
 - 55 (b) un second agent transdermique comprenant une matrice destinée à placer un agent thérapeutique en relation de transmission vers la peau après que l'agent de prévention ou de traitement de réactions cutanées néfastes a été administré de façon transdermique à la peau depuis le premier dispositif transdermique.

23. Système de délivrance transdermique selon la revendication 22, **caractérisé en ce que** les premier et second dispositifs transdermiques sont contenus à l'intérieur d'un seul timbre transdermique.

24. Utilisation d'une quantité efficace d'un agent de prévention de réactions cutanées néfastes comprenant un diurétique de l'anse seul ou en combinaison avec au moins un agent de dégranulation des mastocytes ou au moins un glucocorticostéroïde dans la fabrication d'un médicament qui peut être administré de façon transdermique à un animal à sang chaud, avant, après ou pendant l'administration d'un agent thérapeutique, en vue de prévenir ou de traiter une réaction néfaste de la peau.

25. Utilisation selon la revendication 24, **caractérisée en ce que** le diurétique de l'anse est choisi parmi le groupe constitué de l'acide éthacrynique, du furosémide et du bumétanide.

26. Utilisation selon la revendication 24, **caractérisée en ce que** l'agent de dégranulation des mastocytes est choisi parmi le groupe constitué de l'acide cis-urocanique, des analogues et des métabolites de celui-ci, de la PUVA, de la chloroquine, de l'histamine, de la capsaïcine, du sulfate de morphine, d'un ionophore du canal sodique, d'un ionophore du canal calcique, d'un inhibiteur de la ATPase du canal Na^+/K^+ , de la quinine, de la 4-amino pyridine, de l'anticorps anti-IgE humaine, du composé 48/80, de la substance P, de l'estradiol, de la somatostatine, du carbachol, de la progestérone, du spantide et de la clonidine.

27. Utilisation selon la revendication 26, **caractérisée en ce que** des analogues de l'acide cis-urocanique sont choisis parmi le groupe constitué de l'acide 1-furane-acrylique, de l'acide 2-pyrole-acrylique, de l'acide 2-thiophène-acrylique, de l'acide dihydro-urocanique et de l'acide trans-urocanique.

28. Utilisation selon la revendication 24, **caractérisée en ce que** le glucocorticostéroïde est choisi parmi le groupe constitué de l'hydrocortisone et des analogues de celle-ci, de la béclo méthasone, de la bétaméthasone et des analogues de celle-ci, du clobétasol et des analogues de celui-ci, du désônide, de la dexaméthasone, du fluocinonide, de la prednisone et de la triamcinolone.